Search
Search
ASRS: 2022
Arshad M. Khanani, MD, MA
Show Description +
Arshad M. Khanani, MD, MA, shares late-breaking 2-year safety and efficacy data from the phase 3 trials for faricimab (Vabysmo, Genentech/Roche) in wet AMD.
Posted: 7/26/2022
Arshad M. Khanani, MD, MA
Arshad M. Khanani, MD, MA, shares late-breaking 2-year safety and efficacy data from the phase 3 trials for faricimab (Vabysmo, Genentech/Roche) in wet AMD.
Posted: 7/26/2022
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2022.
Please log in to leave a comment.